Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027
January 30, 2024 20:25 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global scleroderma market is poised for...
Scleroderma Therapeutics Market is estimated to be US$ 4.3 Billion by 2032; Growing Incidence and Screening Rates of Scleroderma to Fuel-By PMI
September 18, 2023 13:30 ET
|
PMI
Covina, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Scleroderma, also known as systemic sclerosis, is a rare and chronic autoimmune disease that primarily affects the connective tissues in the body. There...
Autoimmune Disease Testing Market is set to reach revenue of US$ 15.75 Billion, expected to grow at 10% CAGR during 2023 to 2033 period | Future Market Insights, Inc.
April 10, 2023 03:55 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 10, 2023 (GLOBE NEWSWIRE) -- According to FMI estimations, the Autoimmune Disease Testing Market could increase from US$ 6.07 billion in 2023 to US$ 15.75 billion by 2033. The...
AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients
July 26, 2022 17:50 ET
|
Aisa Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
March 30, 2022 08:00 ET
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
January 12, 2022 07:30 ET
|
APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
August 14, 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
July 26, 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Story of Traumatic Brain Injury Wins #IAmInvisibleNoMore Video Contest
May 04, 2018 17:10 ET
|
Allsup
Belleville, Illinois, May 04, 2018 (GLOBE NEWSWIRE) -- The Invisible Disabilities Association (IDA), an organization dedicated to raising worldwide awareness of invisible disabilities, and Allsup,...
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
June 21, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., June 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...